Ci Capital Analyst Recommendations & Stock PicksView the latest stock recommendations issued by analysts at Ci Capital. This page tracks publicly reported analyst upgrades and downgrades, buy/hold/sell ratings, and price target changes for publicly traded companies. All data is compiled from credible public sources and updated regularly to reflect new insights from Ci Capital's equity research team. MarketBeat is not affiliated with or endorsed by Ci Capital.Updated 3/27/2026 Brokerage RankingSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROITotal Ratings2 Last 12 MonthsBuy Ratings1 Last 12 MonthsSell Ratings0 Last 12 MonthsCompanies Covered2 Last 12 Months Country All Countries USA (NYSE & NASDAQ)USA (All Exchanges)CanadaUnited Kingdom Sector All Sectors AerospaceAuto/Tires/TrucksBasic MaterialsBusiness ServicesCommunication ServicesComputer and TechnologyConstructionConsumer CyclicalConsumer DefensiveConsumer DiscretionaryConsumer GoodsConsumer StaplesEnergyFinanceFinancial ServicesIndustrialsManufacturingMedicalMiscellaneousMulti-Sector ConglomeratesReal EstateRetail/WholesaleServicesTransportationUtilities Market Cap All MarketCaps Mega Cap (More Than $200B)Large Cap ($10B-$200B)Mid Cap ($2B-$10B)Small Cap ($300M-$2B)Micro Cap ($50M-$300M)Nano Cap (Under $50M) MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.Available with a MarketBeat All Access SubscriptionMarketRank™Upgrade to All Access to use the All Ranks Filter Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.Available with a MarketBeat All Access SubscriptionMedia SentimentUpgrade to All Access to use the All Sentiments Filter Analyst consensus is the average investment recommendation among Wall Street research analysts.Available with a MarketBeat All Access SubscriptionAnalyst ConsensusUpgrade to All Access to use the All Ratings Filter Reporting Date Full History Latest Per Company Show All Ratings Strong Buy Buy Hold Sell Rating All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Price Target Change Action Any Change Raised 5%+ Raised 10%+ Raised 20%+ Lowered 5%+ Lowered 10%+ Lowered 20%+ Price Target Change Export CompanyCurrent PriceReport DateAnalystActionPrice TargetRating12-Month Recommendation ROIDetailsDOOBRPC$77.11+2.6%3/27/2026 Lower Price TargetC$128.00 ➝ C$119.00Buy00.00%View details for Ci Capital rating of BRP (TSE:DOO) on 3/27/2026LUNLundin MiningC$41.37-1.5%2/11/2026 Boost Price TargetC$32.00 ➝ C$41.0000.00%View details for Ci Capital rating of Lundin Mining (TSE:LUN) on 2/11/2026MDAMDA SpaceC$53.79+2.5%11/18/2024 Boost Price TargetC$15.00 ➝ C$26.0000.00%View details for Ci Capital rating of MDA Space (TSE:MDA) on 11/18/2024TPZTopaz EnergyC$32.56+1.8%1/17/2023 Lower Price TargetC$29.00 ➝ C$27.0000.00%View details for Ci Capital rating of Topaz Energy (TSE:TPZ) on 1/17/2023FRUFreehold RoyaltiesC$17.66+1.4%8/12/2021 Boost Price TargetC$12.5000.00%View details for Ci Capital rating of Freehold Royalties (TSE:FRU) on 8/12/2021IFRXInflaRx$2.38-5.6%9/14/2020 Reiterated Rating$7.00Hold00.00%View details for Ci Capital rating of InflaRx (NASDAQ:IFRX) on 9/14/2020CALTCalliditas Therapeutics AB (publ)$40.008/18/2020 Reiterated Rating$44.00Buy00.00%View details for Ci Capital rating of Calliditas Therapeutics AB (publ) (NASDAQ:CALT) on 8/18/2020CBIOCrescent Biopharma$21.23+8.3%8/6/2020 Reiterated Rating$1,800.00Buy00.00%View details for Ci Capital rating of Crescent Biopharma (NASDAQ:CBIO) on 8/6/2020VYNEVYNE Therapeutics$0.67+0.1%8/6/2020 Reiterated Rating$504.00Buy00.00%View details for Ci Capital rating of VYNE Therapeutics (NASDAQ:VYNE) on 8/6/2020IMVTImmunovant$28.96-1.0%8/5/2020 Reiterated Rating$32.00Buy00.00%View details for Ci Capital rating of Immunovant (NASDAQ:IMVT) on 8/5/2020RCKTRocket Pharmaceuticals$3.40-5.6%8/5/2020 Reiterated Rating$35.00Buy00.00%View details for Ci Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 8/5/2020CBIOCrescent Biopharma$21.23+8.3%7/22/2020 Reiterated Rating$1,900.00Buy00.00%View details for Ci Capital rating of Crescent Biopharma (NASDAQ:CBIO) on 7/22/2020IFRXInflaRx$2.38-5.6%5/28/2020 Reiterated Rating$7.00Hold00.00%View details for Ci Capital rating of InflaRx (NASDAQ:IFRX) on 5/28/2020AGF.BAGF ManagementC$16.95+3.0%3/28/2019 Lower Price TargetC$6.50 ➝ C$6.0000.00%View details for Ci Capital rating of AGF Management (TSE:AGF.B) on 3/28/2019CASCascadesC$10.49+0.1%7/4/2017 Boost Price TargetC$17.00 ➝ C$19.0000.00%View details for Ci Capital rating of Cascades (TSE:CAS) on 7/4/2017CASCascadesC$10.49+0.1%4/7/2017 Boost Price TargetC$17.00 ➝ C$19.0000.00%View details for Ci Capital rating of Cascades (TSE:CAS) on 4/7/2017WSPWSP GlobalC$190.99-1.6%4/1/2014 Boost Price TargetC$38.00 ➝ C$40.0000.00%View details for Ci Capital rating of WSP Global (TSE:WSP) on 4/1/2014QBR.BQuebecorC$62.07+7.8%8/9/2013 Boost Price TargetC$47.00 ➝ C$51.0000.00%View details for Ci Capital rating of Quebecor (TSE:QBR.B) on 8/9/2013 MarketBeat Community Rating for Ci CapitalMarketBeat's community ratings are surveys of what our community members think about Ci Capital and other research firms in the last 90 days. Vote "Outperform" if you believe Ci Capital's recommendations will outperform the broader market over the long term. Vote "Underperform" if you believe Ci Capital's recommendations will underperform the broader market over the long term. You may vote once every thirty days. Log in to vote on this brokerage. COMMUNITY RATINGS2.6out of 5 (last 90 days)2.6 of 5 stars OUTPERFORM VOTES 35 Believe will outperform the market UNDERPERFORM VOTES 33 Believe will underperform the market Ci Capital Stock Coverage by SectorCi Capital concentrates its research most heavily in Basic Materials (50.0%) and Consumer Cyclical (50.0%). The chart below shows how Ci Capital's 2 rated companies are distributed across all 2 sectors it covers.Basic Materials1 company50.0%Consumer Cyclical1 company50.0%Best & Worst CallsBest Call000.0%LON:CEYReiterated Rating • Mar 15, 2016Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%NASDAQ:IMVTReiterated Rating • Aug 5, 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Similarly Rated FirmsParadigm CapitalBEBeaufort SecuritiesZelman & AssociatesLaidlawMaxim GroupAscendiant Capital MarketsPeel HuntShore Capital GroupLiberum CapitalLitchfield Hills Research Ci Capital - Frequently Asked Questions What stocks does Ci Capital currently recommend buying? Ci Capital's analysts currently have buy-equivalent ratings on 1 companies. What sectors does Ci Capital specialize in? Ci Capital has the deepest coverage in Consumer Cyclical (50.0% of rated companies) and Basic Materials (50.0% of rated companies). How often does Ci Capital change its stock ratings? Ci Capital issued 2 ratings over the last 12 months across 2 companies — an average of roughly 0 rating actions per month. These include boost price target and lower price target. MarketBeat tracks every rating change as it's published so you can see the most current Ci Capital analyst actions. Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageMorgan StanleyJefferies Financial GroupStifel NicolausOppenheimerBerenberg BankRoth MkmWall Street ZenUBS GroupCitigroupBarclaysWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.The Goldman Sachs GroupTD Cowen Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
